Clinical trial

Study Evaluating Temsirolimus (CCI-779) In Breast Neoplasms

NCT00062751

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2002-12-01

PhasePHASE2

Study timeline

Study start (unknown)2002-12-01Date precision: month

Registry last updated2011-04-15

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Breast Neoplasmsunresolved

Interventions

Letrozole / Temsirolimus (CCI-779)DRUG

LetrozoleDRUG · verified · RxNorm: letrozole

Sponsors & collaborators

Wyeth is now a wholly owned subsidiary of Pfizerlead sponsor

Pfizercollaborator

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT00062751 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.